APC 8020

Drug Profile

APC 8020

Alternative Names: APC8020; Multiple myeloma vaccine - Dendreon; Myeloma vaccine - Dendreon; Mylovenge

Latest Information Update: 22 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dendreon Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Amyloidosis; Multiple myeloma

Most Recent Events

  • 11 Oct 2004 No development reported - Phase-I for Multiple myeloma in Japan (unspecified route)
  • 11 Oct 2004 No development reported - Phase-II for Amyloidosis in USA (unspecified route)
  • 11 Oct 2004 No development reported - Phase-II for Multiple myeloma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top